XCUR - Checkmate Pharmaceuticals Begins IPO Process
Quick Take
Checkmate Pharmaceuticals (CMPI) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer.
CMPI has produced promising early trial results and has significant collaboration partnerships with major pharma firms.
I’ll provide a final opinion when we learn more about the IPO from management.
Company & Technology
Cambridge, Massachusetts-based Checkmate was founded to develop its CMP-001 candidate, a Toll-like receptor 9, TLR9 'agonist